Pharma giant Pfizer has been given a price target boost by Bank of America this week, as well as a reiterated “buy” rating. Analyst Jason Gerberry of Bank of America believes that Pfizer is positioned to benefit from some key second-half catalysts. The analyst boosted his price target from $45 a share to $48 a … Continue reading “Bank of America Just Gave Pfizer a Price Target Increase for This Reason”
